Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2016 Planned number of patients changed from 224 to 180.
- 22 Jan 2016 Planned number of patients changed from 380 to 224, as reported by ClinicalTrials.gov record.